{"disease":{"id":"lennox-gastaut-syndrome","name":"Lennox-Gastaut syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":18,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cannabidiol","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epidiolex","generic_name":"CANNABIDIOL","company_name":"Jazz Pharms Res","drug_phase":"marketed","molecular_target":"Caspase-1","drug_class":"","quality_score":69,"revenue":"800","mechanism":"Epidiolex works by inhibiting the activity of caspase-1, a protein involved in the inflammatory response and neuronal excitability."},{"drug_id":"clonazepam","indication_name":"Lennox-Gastaut Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klonopin","generic_name":"clonazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"topiramate","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topamax","generic_name":"topiramate","company_name":"Janssen","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"phenytoin","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"clobazam","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onfi","generic_name":"CLOBAZAM","company_name":"Lundbeck Pharms Llc","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":"Onfi works by enhancing the activity of the neurotransmitter GABA, which helps calm excessive electrical activity in the brain."},{"drug_id":"bat","indication_name":"Treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"carbamazepine","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"lorazepam","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ativan","generic_name":"lorazepam","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lamotrigine","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"rufinamide","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Banzel","generic_name":"RUFINAMIDE","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"rufinamide","quality_score":10,"revenue":null,"mechanism":"Banzel works by stabilizing inactivated sodium channels in the brain, reducing the frequency of seizures."},{"drug_id":"clonazepam","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klonopin","generic_name":"clonazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"carbamazepin","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"phenobarbitone","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"primidone","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mysoline","generic_name":"PRIMIDONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 3","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"felbamate","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Felbatol","generic_name":"FELBAMATE","company_name":"Mylan Speciality Lp","drug_phase":"marketed","molecular_target":"NMDA receptor-ionophore complex","drug_class":"Anti-epileptic Agent [EPC]","quality_score":80,"revenue":null,"mechanism":"Felbamate's exact mechanism is unknown, but it shows anticonvulsant activity in various animal models and interacts with the NMDA receptor-ionophore complex."},{"drug_id":"dilantin","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"rufinamid","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rufinamid","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, Sodium channel alpha subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"topamax","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Topamax","company_name":"Ataturk University","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epidiolex","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epidiolex","company_name":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","drug_phase":"marketed","molecular_target":"N-arachidonyl glycine receptor, Cannabinoid receptor 2, Caspase-1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rufinamide","indication_name":"Seizures associated with Lennox-Gastaut Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Banzel","generic_name":"RUFINAMIDE","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"rufinamide","quality_score":10,"revenue":null,"mechanism":"Banzel works by stabilizing inactivated sodium channels in the brain, reducing the frequency of seizures."},{"drug_id":"klonopin","indication_name":"Lennox-Gastaut syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Klonopin","company_name":"Par Pharmaceutical, Inc.","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05374824","title":"Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":4680,"lead_sponsor_name":"Ann & Robert H Lurie Children's Hospital of Chicago","has_results":false},{"nct_id":"NCT02175173","title":"Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":707,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT02224573","title":"An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":681,"lead_sponsor_name":"GW Research Ltd","has_results":true},{"nct_id":"NCT03936777","title":"A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":412,"lead_sponsor_name":"Zogenix, Inc.","has_results":true},{"nct_id":"NCT05163314","title":"A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":352,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03355209","title":"A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","has_results":true},{"nct_id":"NCT04938427","title":"A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05066217","title":"An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Epygenix","has_results":false},{"nct_id":"NCT05982717","title":"A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain","phase":"","overall_status":"COMPLETED","enrollment_count":237,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02224560","title":"Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT02224690","title":"A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":171,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT03635073","title":"A Study of Soticlestat in Adults and Children With Rare Epilepsies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":156,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05044819","title":"Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT03650452","title":"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":141,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02834793","title":"Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":101,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT05364021","title":"Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Longboard Pharmaceuticals","has_results":false},{"nct_id":"NCT05626634","title":"Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Longboard Pharmaceuticals","has_results":false},{"nct_id":"NCT01405053","title":"Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT05339126","title":"RNS System LGS Feasibility Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"NeuroPace","has_results":false},{"nct_id":"NCT06924086","title":"The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT07225231","title":"Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Byteflies","has_results":false},{"nct_id":"NCT06401538","title":"BMB-101 in Absence Epilepsy and DEE","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Bright Minds Biosciences Pty Ltd","has_results":false},{"nct_id":"NCT03731715","title":"Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"SK Life Science, Inc.","has_results":false},{"nct_id":"NCT04062981","title":"Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"SK Life Science, Inc.","has_results":false},{"nct_id":"NCT03467113","title":"A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","has_results":false},{"nct_id":"NCT03955432","title":"Long-term Cardiac Monitoring in Epilepsy","phase":"NA","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT06464653","title":"Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut Syndrome","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5,"lead_sponsor_name":"Liankun_Ren","has_results":false},{"nct_id":"NCT05437393","title":"Children's Adaptive Deep Brain Stimulation for Epilepsy Trial (CADET): Pilot","phase":"NA","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04485104","title":"Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT02815540","title":"The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Gillette Children's Specialty Healthcare","has_results":true},{"nct_id":"NCT06422377","title":"A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06395792","title":"A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, Teenagers and Adults in Portugal","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02318537","title":"Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"INSYS Therapeutics Inc","has_results":false},{"nct_id":"NCT02307578","title":"An Extended Access Program (EAP) for Perampanel","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Eisai Inc.","has_results":false},{"nct_id":"NCT03778424","title":"An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Eisai Inc.","has_results":false},{"nct_id":"NCT06149663","title":"Intermediate-Size Expanded Access Protocol (EAP) for LP352","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Longboard Pharmaceuticals","has_results":false}],"total":36},"guidelines":[],"source":"Drug Landscape verified database"}